VERVE 201
Alternative Names: ANGPTL3 targeted gene editing therapy - Verve Therapeutics; VERVE-201Latest Information Update: 28 Jun 2025
At a glance
- Originator Broad Institute; Harvard University
- Developer Verve Therapeutics
- Class Antihyperlipidaemics; Gene therapies; RNA
- Mechanism of Action ANGPTL3 protein expression inhibitors; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hypercholesterolaemia
- No development reported Hyperlipoproteinaemia type IIa
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Hyperlipoproteinaemia-type-IIa in USA (IV, Infusion)
- 30 Oct 2024 Phase-I clinical trials in Hypercholesterolaemia (Treatment-experienced) in United Kingdom, Canada (IV) (NCT06451770)
- 23 May 2024 Verve Therapeutics plans a phase Ib trial for Hyperlipoproteinaemia type IIa in H2 2024